Maybe so Mr Dingo,
We know that Her2 positive GEJ Ca is far more common in the Asian population. In combo with Keytruda as well, which off patent in the near future unless Merck miraculously manage to fluff that out somehow?
The primary completion date is 03/2024, but it appears all actively recruiting sites still are doing so, unless we are due an update on NextHorizon trial?
Ann: Phase 1 CF33-hNIS Study Update - Positive Early Signals, page-120
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
